BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer
- PMID: 30797818
- DOI: 10.1016/j.canlet.2019.02.027
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer
Abstract
This study investigated the prevalence of TIL subpopulations, TLS, PD-1 and PD-L1 in tumors from TNBC patients harboring wild-type or mutated BRCA1 or BRCA2 germline genes. This TNBC cohort included 85% TIL-positive (≥10%) tumors with 21% classified as TILhi (≥50%). Interestingly, the BRCAmut group had a significantly higher incidence of TILpos tumors compared to the BRCAwt group (P = 0.037). T cells were dominant in the infiltrate but no statistically significant differences were detected between BRCAwt and BRCAmut for CD3+, CD4+ and CD8+ T cells or CD20+ B cells. TLS were detected in 74% of tumors but again no significant differences between the BRCA groups. PD-1 expression was observed in 33% and PD-L1 in 53% (any cell, cut-off ≥1%) tumors for the entire TNBC cohort. PD-1 expression correlated with PD-L1 and both with TIL and TLS but was not associated with BRCA mutational status. Our analyses reveal that BRCAwt and BRCAmut TNBC are similar except for a significant increase of TILpos tumors in the BRCAmut group. While BRCA gene mutations may not directly drive immune infiltration, the greater number of TILpos tumors could signal greater immunogenicity in this group.
Keywords: BRCA gene mutations; PD-1 and PD-L1; Tertiary lymphoid structures; Triple negative breast cancer; Tumor infiltrating lymphocytes.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.Breast Cancer. 2020 Jul;27(4):519-526. doi: 10.1007/s12282-020-01110-2. Epub 2020 May 23. Breast Cancer. 2020. PMID: 32447649
-
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9. Breast Cancer. 2018. PMID: 28488168
-
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.Cancer Res Treat. 2019 Apr;51(2):649-663. doi: 10.4143/crt.2018.270. Epub 2018 Jul 31. Cancer Res Treat. 2019. PMID: 30064200 Free PMC article.
-
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Med Mol Morphol. 2017. PMID: 28936553 Review.
-
Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.Cancer. 2018 May 15;124(10):2086-2103. doi: 10.1002/cncr.31272. Epub 2018 Feb 9. Cancer. 2018. PMID: 29424936 Review.
Cited by
-
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.BMC Med. 2024 Jan 9;22(1):9. doi: 10.1186/s12916-023-03233-7. BMC Med. 2024. PMID: 38191387 Free PMC article.
-
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.Front Oncol. 2023 Nov 9;13:1244781. doi: 10.3389/fonc.2023.1244781. eCollection 2023. Front Oncol. 2023. PMID: 38023167 Free PMC article. Review.
-
Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer.Int J Mol Sci. 2023 Oct 16;24(20):15219. doi: 10.3390/ijms242015219. Int J Mol Sci. 2023. PMID: 37894900 Free PMC article.
-
The current advances of lncRNAs in breast cancer immunobiology research.Front Immunol. 2023 Jun 5;14:1194300. doi: 10.3389/fimmu.2023.1194300. eCollection 2023. Front Immunol. 2023. PMID: 37342324 Free PMC article. Review.
-
NAD+ biosynthesis metabolism predicts prognosis and indicates immune microenvironment for breast cancer.Pathol Oncol Res. 2023 Mar 17;29:1610956. doi: 10.3389/pore.2023.1610956. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37006438 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
